ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01239134
Recruitment Status : Recruiting
First Posted : November 11, 2010
Last Update Posted : March 3, 2017
Sponsor:
Collaborator:
Cancer Research Institute, New York City
Information provided by (Responsible Party):
Leap Therapeutics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : October 2018
  Estimated Study Completion Date : December 2018